Boehringer Ingelheim GmbH

Boehringer Ingelheim, Pfizer to jointly market once-a-day SPIRIVA for Chronic Obstructive Pulmonary Disease

    Ingelheim, Germany, and New York (ots-PRNewswire) - Boehringer
Ingelheim and Pfizer Inc announced today that they have entered into
a long-term worldwide agreement to jointly market SPIRIVA(r)
(tiotropium), a novel once-a-day inhaled treatment for Chronic
Obstructive Pulmonary Disease (COPD), which includes chronic
bronchitis and emphysema.
    Boehringer Ingelheim has filed for marketing approval with
regulatory authorities in Europe, where SPIRIVA(r) could be available
as early as mid-2002.  A new drug application  for SPIRIVA(r) is
anticipated to be filed with the  Food and Drug Administration later
this year.
    SPIRIVA(r), discovered and developed by Boehringer Ingelheim,
would be the first once-a-day inhaled bronchodilator treatment for
COPD and represents a significant advance over other treatment
    According to the World Health Organisation, about 600 million
people suffer from COPD, though many are undiagnosed.  The disease
claims three million lives annually.  It is estimated that one in
five smokers will develop COPD.
    "We're very pleased to be working with Pfizer in co-promoting
SPIRIVA(r)," said Prof. Rolf Krebs, Chairman of the Board of Managing
Directors at Boehringer Ingelheim.  "Through this agreement, we gain
a strong and experienced partner who will help increase awareness of
the disease and of the significant patient benefits that this novel
compound delivers."
    "We fully expect SPIRIVA(r) to be an important treatment option
for a condition that is debilitating to patients and costly to health
care systems worldwide," said Pfizer Chief Executive Officer Hank
McKinnell.  "Building on our extensive partnering experience and
combined with Boehringer Ingelheim's established strength and long
experience in respiratory disease management, SPIRIVA(r) should
become the global leader in treating COPD."
    COPD is a chronic respiratory disorder characterised by limited
airflow accompanied by symptoms such as shortness of breath, cough,
wheezing and increased sputum production.  As the disease progresses,
patients become increasingly disabled, although at first they may
attribute their symptoms to ageing.  Currently there are no specific
medications that are fully effective in treating COPD.
    Data from clinical trials involving more than 3,000 patients
worldwide have demonstrated that SPIRIVA(r) is highly effective,
providing sustained bronchodilation with significant symptomatic
improvement in shortness of breath.  Data also indicate that
SPIRIVA(r) reduced exacerbations of COPD, resulting in fewer
hospitalisations. SPIRIVA(r) also was shown to be well tolerated.
    Under terms of the agreement, Boehringer Ingelheim and Pfizer will
conduct additional clinical trials and further develop SPIRIVA(r).
    "We anticipate this will be a long and productive collaboration
with Pfizer in the commercialisation of SPIRIVA(r)," said Dr.
Alessandro Banchi, Member of Boehringer Ingelheim's Board of Managing
Directors who is responsible for pharmaceutical marketing and sales.
    The Boehringer Ingelheim group of companies, with headquarters in
Ingelheim, Germany, is one of the 20 leading pharmaceutical companies
in the world.  In 2000, it posted revenues of more than EUR 6
billion.  Boehringer has some 140 affiliated companies worldwide.
The focus is on the human pharmaceutical and animal health
businesses.  The human pharmaceutical business, which accounts for 95
percent of sales, mainly includes prescription medicines and products
for consumer health care but also products for industrial customers
(chemicals and biopharmaceuticals).
    Substantial research and development, production, and distribution
facilities are located around the globe.  In 2000, Boehringer
Ingelheim spent EUR 1 billion on research and development, equivalent
to 16 percent of net sales.
    For more information on Boehringer Ingelheim, please see the
Internet website
    Pfizer Inc discovers, develops, manufactures and markets leading
prescription medicines for humans and animals, and many of the
world's best-known consumer products.  Pfizer had global revenues of
$29.6 billion in 2000.  Pfizer plans to make a research and
development investment of approximately $5 billion in 2001.
ots Originaltext: Boehringer Ingelheim GmbH

Boehringer Ingelheim GmbH Judith von Gordon or Ulrich Bock, CD
Relations, 55216 Ingelheim
Phone:  + 49 - 6132 - 77-3582/ -2012
Fax: + 49 - 6132 - 77 6601
Pfizer Inc: Mariann Caprino Corporate Media Relations,
Phone: + 1 (212) 733-4554

Weitere Meldungen: Boehringer Ingelheim GmbH

Das könnte Sie auch interessieren: